Location-Specific Hematoma Volume Cutoff and Clinical Outcomes in Intracerebral Hemorrhage.
Kay-Cheong Teo, Sze-Man Fong, William C Y Leung...
https://pubmed.ncbi.nlm.nih.gov/37216445/Actively Recruiting
Led by Southwest Hospital, China · Updated on 2025-05-18
280
Participants Needed
2
Research Sites
26 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of neuroendoscopic surgery compared to traditional craniotomy for treating large intracerebral hemorrhage. This trial addresses the lack of prospective randomized studies on surgical methods for this condition, aiming to provide clearer guidance for treatment decisions. Previous studies suggest neuroendoscopic surgery may reduce surgery time and blood loss while improving recovery and quality of life. Participants will be randomly assigned to one of two groups one receiving neuroendoscopic surgery to remove the brain hematoma, and the other undergoing craniotomy for the same purpose. Both groups will receive standard medical care after surgery. The trial is conducted across multiple centers and includes a single-blinded design. During the study, participants will be monitored for several outcomes, including neurological recovery using the Modified Rankin Scale at 180 days, mortality rates at 30, 90, and 180 days, cognitive function with the Mini-Mental State Examination, and quality of life assessments. Researchers will also track hospital and ICU stay lengths, operation duration, and bleeding during surgery. Follow-up assessments will occur up to 180 days after treatment to evaluate safety and effectiveness.
CONDITIONS
Efficacy and Safety of NeuroEndoscopic Surgery for Large IntraCerebral Hemorrhage
R
Rong Hu, MD
H
Hua Feng, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Southwest Hospital, China
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
screening and enrollment visit
Duration - Up to hospital discharge or 180 days
Participants undergo neuroendoscopic surgery or craniotomy to remove intracranial hematoma, followed by standard medical management.
1 surgery visit and multiple post-operative medical care visits during hospitalization
Duration - Up to 180 days after surgery
Participants are monitored for recovery including neurological function, cognitive assessments, and quality of life evaluations.
Visits at 30 days, 90 days, and 180 days post-surgery
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kay-Cheong Teo, Sze-Man Fong, William C Y Leung...
https://pubmed.ncbi.nlm.nih.gov/37216445/A David Mendelow, Barbara A Gregson, Helen M Fernandes...
https://pubmed.ncbi.nlm.nih.gov/15680453/Gustavo Pradilla, Jonathan J Ratcliff, Alex J Hall...
https://pubmed.ncbi.nlm.nih.gov/38598795/J Claude Hemphill, Steven M Greenberg, Craig S Anderson...
https://pubmed.ncbi.nlm.nih.gov/26022637/J P Broderick, T G Brott, J E Duldner...
https://pubmed.ncbi.nlm.nih.gov/8322400/João Pinho, Ana Sofia Costa, José Manuel Araújo...
https://pubmed.ncbi.nlm.nih.gov/30682522/Daniel F Hanley, Richard E Thompson, Michael Rosenblum...
https://pubmed.ncbi.nlm.nih.gov/30739747/Charlotte Jj van Asch, Merel Ja Luitse, Gabriël Je Rinkel...
https://pubmed.ncbi.nlm.nih.gov/20056489/Steven M Greenberg, Wendy C Ziai, Charlotte Cordonnier...
https://pubmed.ncbi.nlm.nih.gov/35579034/Southwest Hospital, China
Lead Sponsor